{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T15:04:17Z","timestamp":1776265457875,"version":"3.50.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Medical Research and Development Fund administered by the Beijing Kangmeng Charity Foundation","award":["TB219001"],"award-info":[{"award-number":["TB219001"]}]},{"name":"Self-funded research project of the Health Commission of Guangxi Zhuang Autonomous Region","award":["Z-A20240724"],"award-info":[{"award-number":["Z-A20240724"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-025-06673-8","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T07:22:23Z","timestamp":1759994543000},"page":"5181-5190","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Zanubrutinib plus salvage chemotherapy in patients with refractory\/relapsed diffuse large B-cell lymphoma non-candidate for autologous stem cell transplantation: A retrospective study"],"prefix":"10.1007","volume":"104","author":[{"given":"Sha","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dani","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Rong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengcheng","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4700-4562","authenticated-orcid":false,"given":"Xiaohong","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"key":"6673_CR1","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1309\/AJCP7YLTQPUSDQ5C","volume":"138","author":"J Sun","year":"2012","unstructured":"Sun J, Yang Q, Lu Z et al (2012) Distribution of lymphoid neoplasms in China: analysis of 4,638 cases according to the world health organization classification. Am J Clin Pathol 138:429\u2013434. https:\/\/doi.org\/10.1309\/AJCP7YLTQPUSDQ5C","journal-title":"Am J Clin Pathol"},{"key":"6673_CR2","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3322\/caac.21357","volume":"66","author":"LR Teras","year":"2016","unstructured":"Teras LR, DeSantis CE, Cerhan JR et al (2016) 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin 66:443\u2013459. https:\/\/doi.org\/10.3322\/caac.21357","journal-title":"CA Cancer J Clin"},{"key":"6673_CR3","doi-asserted-by":"publisher","first-page":"3121","DOI":"10.1200\/JCO.2005.05.1003","volume":"24","author":"TM Habermann","year":"2006","unstructured":"Habermann TM, Weller EA, Morrison VA et al (2006) Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-Cell lymphoma. JCO 24:3121\u20133127. https:\/\/doi.org\/10.1200\/JCO.2005.05.1003","journal-title":"JCO"},{"key":"6673_CR4","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","volume":"116","author":"B Coiffier","year":"2010","unstructured":"Coiffier B, Thieblemont C, Van Den Neste E et al (2010) Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the groupe d\u2019etudes des lymphomes de l\u2019adulte. Blood 116:2040\u20132045. https:\/\/doi.org\/10.1182\/blood-2010-03-276246","journal-title":"Blood"},{"key":"6673_CR5","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","volume":"130","author":"M Crump","year":"2017","unstructured":"Crump M, Neelapu SS, Farooq U et al (2017) Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 130:1800\u20131808. https:\/\/doi.org\/10.1182\/blood-2017-03-769620","journal-title":"Blood"},{"key":"6673_CR6","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1002\/cac2.12126","volume":"41","author":"S Wang","year":"2021","unstructured":"Wang S, Wang L, Hu J (2021) Outcomes in refractory diffuse large B-cell lymphoma: results from a multicenter real-world study in China. Cancer Commun 41:229\u2013239. https:\/\/doi.org\/10.1002\/cac2.12126","journal-title":"Cancer Commun"},{"key":"6673_CR7","doi-asserted-by":"publisher","first-page":"289","DOI":"10.21147\/j.issn.1000-9604.2021.03.01","volume":"33","author":"J Zhu","year":"2021","unstructured":"Zhu J, Ma J (2021) Chinese society of clinical oncology (CSCO) diagnosis and treatment guidelines for malignant lymphoma 2021 (English version). Chin J Cancer Res 33:289\u2013301. https:\/\/doi.org\/10.21147\/j.issn.1000-9604.2021.03.01","journal-title":"Chin J Cancer Res"},{"key":"6673_CR8","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1038\/nm.3884","volume":"21","author":"WH Wilson","year":"2015","unstructured":"Wilson WH, Young RM, Schmitz R et al (2015) Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. Nat Med 21:922\u2013926. https:\/\/doi.org\/10.1038\/nm.3884","journal-title":"Nat Med"},{"key":"6673_CR9","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2015-2597","volume":"75","author":"N Li","year":"2015","unstructured":"Li N, Sun Z, Liu Y et al (2015) Abstract 2597: BGB-3111 is a novel and highly selective bruton\u2019s tyrosine kinase (BTK) inhibitor. Cancer Res 75:2597. https:\/\/doi.org\/10.1158\/1538-7445.AM2015-2597","journal-title":"Cancer Res"},{"key":"6673_CR10","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa2211582","volume":"388","author":"JR Brown","year":"2023","unstructured":"Brown JR, Eichhorst B, Hillmen P et al (2023) Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med 388:319\u2013332. https:\/\/doi.org\/10.1056\/NEJMoa2211582","journal-title":"N Engl J Med"},{"key":"6673_CR11","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1182\/bloodadvances.2020003698","volume":"6","author":"H Yang","year":"2022","unstructured":"Yang H, Xiang B, Song Y et al (2022) Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma. Blood Adv 6:1629\u20131636. https:\/\/doi.org\/10.1182\/bloodadvances.2020003698","journal-title":"Blood Adv"},{"key":"6673_CR12","doi-asserted-by":"publisher","first-page":"1015081","DOI":"10.3389\/fimmu.2022.1015081","volume":"13","author":"X Yuan","year":"2022","unstructured":"Yuan X, Li X, Huang Y et al (2022) Zanubrutinib plus salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma. Front Immunol 13:1015081. https:\/\/doi.org\/10.3389\/fimmu.2022.1015081","journal-title":"Front Immunol"},{"key":"6673_CR13","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans CP, Weisenburger DD, Greiner TC et al (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275\u2013282. https:\/\/doi.org\/10.1182\/blood-2003-05-1545","journal-title":"Blood"},{"key":"6673_CR14","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and Non-Hodgkin lymphoma: the Lugano classification. JCO 32:3059\u20133067. https:\/\/doi.org\/10.1200\/JCO.2013.54.8800","journal-title":"JCO"},{"key":"6673_CR15","unstructured":"(2017) Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 [EB\/OL]. https:\/\/hcp.myeloma.org.uk\/library\/common-terminology-criteria-for-adverse-events-ctcae-version-5-0-2\/"},{"key":"6673_CR16","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1038\/s41379-021-00954-z","volume":"35","author":"W Zhang","year":"2022","unstructured":"Zhang W, Ao Q, Guan Y et al (2022) A novel diagnostic approach for the classification of small B-cell lymphoid neoplasms based on the nanostring platform. Mod Pathol 35:632\u2013639. https:\/\/doi.org\/10.1038\/s41379-021-00954-z","journal-title":"Mod Pathol"},{"key":"6673_CR17","doi-asserted-by":"publisher","first-page":"4079","DOI":"10.1200\/JCO.2011.35.4423","volume":"29","author":"C Thieblemont","year":"2011","unstructured":"Thieblemont C, Briere J, Mounier N et al (2011) The germinal center\/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed\/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin Oncol 29:4079\u20134087. https:\/\/doi.org\/10.1200\/JCO.2011.35.4423","journal-title":"J Clin Oncol"},{"key":"6673_CR18","doi-asserted-by":"publisher","first-page":"2207948","DOI":"10.1080\/16078454.2023.2207948","volume":"28","author":"R Noel","year":"2023","unstructured":"Noel R, Zemmour C, de Montes C et al (2023) A phase II study of lenalidomide and rituximab (R2) combination in patients with high-risk refractory\/relapsed diffuse large B-cell lymphoma. Hematology 28:2207948. https:\/\/doi.org\/10.1080\/16078454.2023.2207948","journal-title":"Hematology"},{"key":"6673_CR19","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s00277-013-1879-x","volume":"93","author":"JL Vacirca","year":"2014","unstructured":"Vacirca JL, Acs PI, Tabbara IA et al (2014) Bendamustine combined with rituximab for patients with relapsed or refractory diffuse large B cell lymphoma. Ann Hematol 93:403\u2013409. https:\/\/doi.org\/10.1007\/s00277-013-1879-x","journal-title":"Ann Hematol"},{"key":"6673_CR20","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1182\/blood.2018891598","volume":"134","author":"A Goy","year":"2019","unstructured":"Goy A, Ramchandren R, Ghosh N et al (2019) Ibrutinib plus Lenalidomide and rituximab has promising activity in relapsed\/refractory non-germinal center B-cell-like DLBCL. Blood 134:1024\u20131036. https:\/\/doi.org\/10.1182\/blood.2018891598","journal-title":"Blood"},{"key":"6673_CR21","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1182\/blood-2014-08-597914","volume":"125","author":"K Maddocks","year":"2015","unstructured":"Maddocks K, Christian B, Jaglowski S et al (2015) A phase 1\/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed\/refractory non-Hodgkin lymphoma. Blood 125:242\u2013248. https:\/\/doi.org\/10.1182\/blood-2014-08-597914","journal-title":"Blood"},{"key":"6673_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2013.28","volume":"3","author":"W Kraan","year":"2013","unstructured":"Kraan W, Horlings HM, van Keimpema M et al (2013) High prevalence of oncogenic MYD88 and CD79B mutations in diffuse large B-cell lymphomas presenting at immune-privileged sites. Blood Cancer J 3:e139. https:\/\/doi.org\/10.1038\/bcj.2013.28","journal-title":"Blood Cancer J"},{"key":"6673_CR23","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","volume":"37","author":"GW Wright","year":"2020","unstructured":"Wright GW, Huang DW, Phelan JD et al (2020) A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell 37:551\u2013568e14. https:\/\/doi.org\/10.1016\/j.ccell.2020.03.015","journal-title":"Cancer Cell"},{"key":"6673_CR24","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1182\/blood.2022018893","volume":"141","author":"SS Neelapu","year":"2023","unstructured":"Neelapu SS, Jacobson CA, Ghobadi A et al (2023) Five-year follow-up of ZUMA-1 supports the curative potential of Axicabtagene Ciloleucel in refractory large B-cell lymphoma. Blood 141:2307\u20132315. https:\/\/doi.org\/10.1182\/blood.2022018893","journal-title":"Blood"},{"key":"6673_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(23)00345-9","volume":"11","author":"P Abrisqueta","year":"2024","unstructured":"Abrisqueta P, Gonz\u00e1lez-Barca E, Panizo C (2024) Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b\/2 study. Lancet Haematol 11:e136\u2013e146. https:\/\/doi.org\/10.1016\/S2352-3026(23)00345-9","journal-title":"Lancet Haematol"},{"key":"6673_CR26","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1200\/JCO.19.00172","volume":"38","author":"LH Sehn","year":"2020","unstructured":"Sehn LH, Herrera AF, Flowers CR et al (2020) Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 38:155\u2013165. https:\/\/doi.org\/10.1200\/JCO.19.00172","journal-title":"J Clin Oncol"},{"key":"6673_CR27","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1200\/JCO-24-02242","volume":"43","author":"NL Bartlett","year":"2025","unstructured":"Bartlett NL, Hahn U, Kim W-S (2025) Brentuximab vedotin combination for relapsed diffuse large B-cell lymphoma. J Clin Oncol 43:1061\u20131072. https:\/\/doi.org\/10.1200\/JCO-24-02242","journal-title":"J Clin Oncol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06673-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06673-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06673-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T23:02:50Z","timestamp":1763420570000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06673-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":27,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["6673"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06673-8","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,9]]},"assertion":[{"value":"29 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Science and Technology Ethics Committee of Guangxi Medical University Affiliated Cancer Hospital (approval No: KY2025590). The requirement for a consent declaration from participants was waived for this study owing to retrospective nature of the analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}